187 related articles for article (PubMed ID: 30789190)
1. Therapeutic effect of RA223 in the management of breast cancer bone metastases.
Costa RP; Tripoli V; Princiotta A; Murabito A; Licari M; Piazza D; Verderame F; Pinto A
Clin Ter; 2019; 170(1):e1-e3. PubMed ID: 30789190
[TBL] [Abstract][Full Text] [Related]
2. Ra223 in Bone Metastases with Osteolytic Activity.
Costa RP; Cardile D; Murabito A; Tripoli V; Verderame F
World J Nucl Med; 2018; 17(2):116-119. PubMed ID: 29719487
[TBL] [Abstract][Full Text] [Related]
3. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis.
Suominen MI; Wilson T; Käkönen SM; Scholz A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405099
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 dichloride therapy in breast cancer with osseous metastases.
Takalkar A; Paryani B; Adams S; Subbiah V
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26581701
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Suominen MI; Rissanen JP; Käkönen R; Fagerlund KM; Alhoniemi E; Mumberg D; Ziegelbauer K; Halleen JM; Käkönen SM; Scholz A
J Natl Cancer Inst; 2013 Jun; 105(12):908-16. PubMed ID: 23682134
[TBL] [Abstract][Full Text] [Related]
7. CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial.
Coleman R; Brown J; Rathbone E; Flanagan L; Reid A; Kendall J; Howell S; Twelves C; Palmieri C; Anand A; MacPherson I; Brown S
Trials; 2020 Jan; 21(1):89. PubMed ID: 31941523
[TBL] [Abstract][Full Text] [Related]
8. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
Shore ND
Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
[TBL] [Abstract][Full Text] [Related]
10. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
11. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
McGann S; Horton ER
Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
[TBL] [Abstract][Full Text] [Related]
12. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.
Coleman R; Aksnes AK; Naume B; Garcia C; Jerusalem G; Piccart M; Vobecky N; Thuresson M; Flamen P
Breast Cancer Res Treat; 2014 Jun; 145(2):411-8. PubMed ID: 24728613
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
14. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer.
Anido Herranz U; Fernández Calvo O; Afonso Afonso FJ; Rodríguez Martínez de Llano S; Lázaro Quintela M; León Mateos L; Vázquez Estévez S; Antón Aparicio LM
Expert Rev Anticancer Ther; 2015 Mar; 15(3):339-48. PubMed ID: 25555355
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy.
Wenter V; Herlemann A; Fendler WP; Ilhan H; Tirichter N; Bartenstein P; Stief CG; la Fougère C; Albert NL; Rominger A; Gratzke C
Oncotarget; 2017 Jul; 8(27):44131-44140. PubMed ID: 28484088
[TBL] [Abstract][Full Text] [Related]
20. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]